Literature DB >> 33113750

Red emission ratio fluorescent probe for the activity of vanin-1 and imaging in vivo.

Jing Qian1, Liang Zhang2, Jiemin Wang1, Zhidong Teng3, Ting Cao1, Lei Zheng1, Yuping Cao1, Wenwu Qin4, Yun Liu5, Huichen Guo6.   

Abstract

Pantetheinase, also known as Vanin-1, catalyzes pantetheine to decompose into the precursor of CoA - pantothenic acid and aminothiol cysteamine. Studies have shown that Vanin-1 plays an important role in many important physiological pathologies. In this paper, a new red emission ratio fluorescent probe DCM-PA (I640 nm/I564 nm) has been implemented to detect the activity of Vanin-1 in cells and vivo. DCM-PA has short response time (30 min), high selectivity and low sensitivity (DL =0.69 ng/mL). Also, we have applied DCM-PA for imaging in cells and mice, and the results have indicated that the probe has a non-negligible potential for monitoring the activity of Vanin-1 in situ, benefiting further to study the role of Vanin-1 in physiology and pathology. In addition, the up-regulation of this enzyme by starvation confirmed the inevitable connection between diabetes and abnormal expression of Vanin-1.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Diabetes; Imaging in vivo; Red emission; Starvation-induced; Vanin-1

Mesh:

Substances:

Year:  2020        PMID: 33113750     DOI: 10.1016/j.jhazmat.2020.123863

Source DB:  PubMed          Journal:  J Hazard Mater        ISSN: 0304-3894            Impact factor:   10.588


  2 in total

1.  A NIR fluorescent probe for Vanin-1 and its applications in imaging, kidney injury diagnosis, and the development of inhibitor.

Authors:  Zhenhao Tian; Fei Yan; Xiangge Tian; Lei Feng; Jingnan Cui; Sa Deng; Baojing Zhang; Tian Xie; Shanshan Huang; Xiaochi Ma
Journal:  Acta Pharm Sin B       Date:  2021-06-08       Impact factor: 11.413

2.  Visualization-Based Discovery of Vanin-1 Inhibitors for Colitis.

Authors:  Guankai Wang; Jingjing Wang; Lupei Du; Minyong Li
Journal:  Front Chem       Date:  2022-01-28       Impact factor: 5.221

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.